The overall goals of this project are to develop a novel quantitative laboratory test to detect cmvIL-10 in human serum and to evaluate whether cmvIL-10 serum levels correlate with breast cancer. The cmvIL-10 protein is a homolog of human IL-10 that binds the cellular IL-10 receptor and displays many of the same immune-suppressive functions of human IL-10, despite having limited amino acid sequence identity to the cellular cytokine. Elevated levels of IL-10 are frequently detected in the serum of cancer patients and correlate with poor prognosis. In this study, the research team plans to utilize the Army of Women to recruit 300 female volunteers; 150 healthy women and 150 women with varying stages of breast cancer. The volunteers will be asked for a blood sample which will be used to determine HCMV serostatus and to screen for levels of both human IL-10 and cmvIL-10.
The purpose of this study was to evaluate cmIL-10 levels in healthy women and women with breast cancer. The research team was investigating whether this test can be used to identify patients who are most likely to benefit from anti-viral drug treatments or monitor how their cancer is responding to treatment. The researchers turned to the Army of Women (AOW) to enroll up to 150 volunteers in the San Francisco, California, area. The Call to Action for this study was sent to AOW members on September 16, 2015. The researchers closed enrollment on August 22, 2016, after the AOW provided them with 146 women who were interested in enrolling in the study.
A Conversation with Dr. Juliet Spencer